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ABSTRACT
L. lactis is a GRAS (“Generally Regarded As Safe”) gram-positive bacterium that does not colonize the digestive tract and has been proposed as a potential in vivo vaccine 
or therapeutic agent carrier. α-sarcin (αS) is an antitumoral toxic protein that is very similar to Asp f 1, the major allergen of Aspergillus fumigatus. We have cloned and 
produced extracellularly in L. lactis several variants of αS and Asp f 1, as well as their natural versions. These include: both wild-type proteins, αS H137Q (a properly folded 
catalytically inactive and non toxic variant of αS), αS Δ(7-22) and Asp f 1 Δ(7-22) (catalytically active but non toxic variants with reduced IgE responses). At this moment, 
fungal allergic and colon cancer mice models are being developed in order to test the potential therapeutic effects of the different L. lactis strains produced.
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plasmids
P1: constitutive promoter P1.
usp45 and SSprtP: secretion sequences.
spaX and ANCHprtP: cell wall anchorage sequences.
ermR: erythromycin resistance genes.
Introducing a STOP codon at 3’ of the 
gene allows protein secretion to 
extracellular medium
The digestive tract is inhabited by commensal flora, whose correct settlement has 
been shown to be very important for human health. In fact, some pathological states can 
be improved by means of administration of certain live bacteria, the so-called probiotics 
[1]. In the last years, the setting-up of genetic engineering techniques has made possible 
the genetic modification of commensal bacteria in order to obtain “biodrugs”, i.e., 
strains of bacteria capable of producing drugs, antimicrobial agents or vaccines in vivo
[2, 3]. One of the advantages of the “biodrugs” is the specific delivery of the therapeutic 
agent to their target.
Lactococcus lactis (L. lactis) is a lactic acid bacteria which holds GRAS (“Generally 
Regarded As Safe”) status and does not colonize the digestive tract. L. lactis is hence a 
suitable candidate to be used as a “biodrug”. In fact, IL-10 producing L. lactis have been 
useful in the treatment of Inflammatory Bowel Disease in mice [4].
The present study deals with two toxic proteins, α-sarcin (αS) and Asp f 1. αS is a 150-
amino-acid protein from Aspergillus giganteus that was firstly characterized as an 
antitumoral agent [5]. αS selectively cleaves one specific bond of the larger rRNA, 
resulting in ribosome inactivation. Despite the antitumoral properties of αS, its lack of 
absolute specificity regarding its cytotoxicity does not allow using it as a therapeutic 
agent. Asp f 1, which displays 87% of sequence identity with αS, is another cytotoxin but 
also the major allergen of Aspergillus fumigatus [6]. Thus, the design of “biodrugs”
based on these two proteins would be interesting to test their therapeutic properties on 
colon cancer and bronchopulmonary aspergillosis (ABPA).
In this work, the extracellular production in L.  lactis of some variants of αS and Asp f 
1 is presented. These include both wild type proteins, αS H137Q (a properly folded 
catalically inactive and non toxic variant of αS) [7] and both αS and Asp f 1 Δ(7-22) 
(catalically active but non toxic variants with reduced IgE responses) [6, 8].
Cloning 
strategy
cDNA’s amplification using Taq Polymerase
(introduction of NgoM IV and BamH I restriction sites)
Subcloning in pCR®2.1-TOPO® plasmid
Digestion with NgoM IV and BamHI and
isolation of the appropriate fragments
Ligation with pT1NX and pT1NXssAnch
digested with NgoM IV and BamH I
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PCR’s amplificates of αS to 
be cloned in (A) pT1NX and 
(B) pT1NXssAnch.
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NgoM IV and BamHI digested (A) pT1NX,  (B) 
pT1NXssAnch, αS cDNA’s to be cloned in (C) 
pT1NX and (D) pT1NXssAnch.
L. lactis MG1363 were 
transformed by electroporation 
with phenolized ligation 
mixtures (60% of recombinant 
colonies were obtained)
Equivalent results were obtained with 
cDNA’s codifying for αS H137Q, Asp f 
1 and both Δ(7-22) variants. 
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Extracellular 
expression 
of αS versus pH
A L. lactis strain carrying pT1NX-αS was grown in M17, 
0.5% glucose, 5 μg/ml erythromycin to OD600= 0.3 – 0.5. 
Then, it was placed in M9-based production media buffered 
at different pH’s with 0.2 M phosphate and allowed to grow 
for 5 hours. Extracellular protein expression was analyzed 
after 20-fold media concentration.
Optimal αS 
expression (~ 0.1 
mg/L) is achieved at 
7.8 initial pH, mostly 
due to a minor 
extent of 
degradation
Initial pH 6.0 6.5 6.9 7.4 7.8 8.1 8.4
Final pH 4.4 5.8 6.6 7.0 7.3 7.4 7.5
L. lactis colonies carrying 
pT1NXssAnch-αS produced much 
less protein. Consequently, all 
other variants were exclusively 
cloned in pT1NX.
Extracellular expression of αS H137Q, 
αS Δ(7-22), Asp f 1 and Asp f 1 Δ(7-22)
All the protein expressions were performed at 7.8 initial pH. 
Two single colonies were assayed for each variant.
αS variants
αS H137Q      αS Δ(7-22)    +        - αS Asp f 1   Asp f 1 Δ(7-22)  +        - Asp f 1
The production media from single colonies 
carrying (+) pT1NX-αS or (-) pT1NX were used as 
positive and negative controls, respectively. 50 ng 
of αS or Asp f 1 were also loaded into the gel.
Asp f 1 variants
Each variant has been 
produced in similar 
quantities to αS
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production media are 
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(Coomassie Blue) or 50 ng 
(Blotting anti-αS ) of αS.
